Belbuca Film, Soluble
NDC 59385-027
Product Information
Belbuca (buprenorphine hydrochloride) is a NDA-approved product labeled by Biodelivery Sciences International Inc. Buprenorphine is used to help relieve severe ongoing pain. It is supplied as a yellow film, soluble for buccal administration. This product entry covers the primary NDC 59385-027 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
24 MM
9 MM
14 MM
19 MM
23 MM
28 MM
E0
E1
E3
E4
E6
E7
E9
Code Structure Chart
Product Details
What is NDC 59385-027?
What are the uses of this product?
What are Active Ingredients of this product?
- BUPRENORPHINE HYDROCHLORIDE 900 ug/1 - A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- BUPRENORPHINE HYDROCHLORIDE (UNII: 56W8MW3EN1)
- BUPRENORPHINE (UNII: 40D3SCR4GZ) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- HYDROXYETHYL CELLULOSE (280 MPA.S AT 5%) (UNII: B24JYI97VR)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- PEPPERMINT OIL (UNII: AV092KU4JH)
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
- SODIUM BENZOATE (UNII: OJ245FE5EU)
- METHYLPARABEN (UNII: A2I8C7HI9T)
- PROPYLPARABEN (UNII: Z8IX2SC1OH)
- FERRIC OXIDE YELLOW (UNII: EX438O2MRT)
- ANHYDROUS CITRIC ACID (UNII: XF417D3PSL)
- .ALPHA.-TOCOPHEROL ACETATE (UNII: 9E8X80D2L0)
- SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS (UNII: KH7I04HPUU)
- SODIUM HYDROXIDE (UNII: 55X04QC32I)
- POLYCARBOPHIL (UNII: W25LM17A4W)
- HYDROXYPROPYL CELLULOSE (90000 WAMW) (UNII: UKE75GEA7F)
- CARBOXYMETHYLCELLULOSE SODIUM (0.7 CARBOXYMETHYL SUBSTITUTION PER SACCHARIDE; 38 MPA.S AT 2%) (UNII: YGX74DKE74)
- SACCHARIN SODIUM (UNII: SB8ZUX40TY)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1716057 - buprenorphine HCl 150 MCG Buccal Film
- RxCUI: 1716057 - buprenorphine 0.15 MG Buccal Film
- RxCUI: 1716063 - Belbuca 150 MCG Buccal Film
- RxCUI: 1716063 - buprenorphine 0.15 MG Buccal Film [Belbuca]
- RxCUI: 1716063 - Belbuca 0.15 MG (as buprenorphine HCl) Buccal Film
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.
Patient Education
Buprenorphine Buccal (chronic pain)
Buprenorphine (Belbuca) is used to relieve severe pain in people who are expected to need pain medication around the clock for a long time and who cannot be treated with other medications. Buprenorphine (Belbuca) should not be used to treat pain that can be controlled by medication that is taken as needed. Buprenorphine (Belbuca) in a class of medications called opiate partial agonists. It works by changing the way the brain and nervous system respond to pain.
[Learn More]
Buprenorphine Sublingual and Buccal (opioid dependence)
Buprenorphine and the combination of buprenorphine and naloxone are used to treat opioid dependence (addiction to opioid drugs, including heroin and narcotic painkillers). Buprenorphine is in a class of medications called opioid partial agonist-antagonists and naloxone is in a class of medications called opioid antagonists. Buprenorphine alone and the combination of buprenorphine and naloxone work to prevent withdrawal symptoms when someone stops taking opioid drugs by producing similar effects to these drugs.
[Learn More]
* Please review the full disclaimer at the bottom of this page.